HOPEWIND-ELECTRIC
28.5.2024 13:17:33 CEST | Business Wire | Press release
Hopewind (SHANGHAI STOCK EXCHANGE Code: 603063) has been officially nominated for the 2024 Smarter E award for its grid forming capable 385 kW utility-scale string inverter. Selected by jury for the Top 10 short list, makes Hopewind the only Chinese solar inverter manufacturer to reach the finals, highlighting the company's strong R&D capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527117090/en/
Hopewind has been officially nominated for the 2024 Smarter E award (Photo: Business Wire)
“Our nomination for The Smarter E / Intersolar Award 2024 underlines our innovative nature that is core to our DNA,” said Wang Yao, Deputy General Manager of Hopewind.
Also in May, the Q2/2004 Global PV Market Outlook of Bloomberg New Energy Finance (BNEF) selected Hopewind to join its Tier 1 Photovoltaic Inverter Manufacturer list. “Ranking on BNEF’s prestigious Tier 1 list recognizes our financial and business strengths,” added Wang Yao, “and it confirms our strategy to delve deeper into the PV field, working on further innovations and breakthroughs to lead the development of global clean and renewable energy.”
As part of its innovation strategy, Hopewind officially joined the International Solar Energy Research Center Konstanz (ISC), one of world solar leading research institutes in April. Established in 2007, Hopewind was listed on the Shanghai Stock Exchange (Stock code: 603063) in 2017 as a leading innovator in the clean power generation industry, specializing in designing and producing renewable and electrical solutions, including wind power converters, PV inverters, battery storage systems (BESS), SVG, and industry drives with 150 GW+ shipments worldwide and GW production capacities.
Hopewind, participated in the Wingrid project, supported by the Horizon Europe 2020 and facilitated through the DNV Netherlands Laboratory. In 2023, Hopewind’s wind power converter received the world’s first grid forming certificate from DNV, with the 385kW inverter being selected as No.1 powerful solar string inverter by Solarbe Global since February, 2024.
Like in the Kubuqi Desert of Inner Mongolia, the seventh largest desert in China, an impressive transformation is taking place. Beneath over 10 kilometers of photovoltaic (PV) panels, herbs and pasture thrive, while chickens and goats roam and forage, bringing new life to the arid landscape.
The solar energy captured by these panels is converted into clean electricity by Hopewind 5,604 350kW inverters and fed into the power grid.
“This project showcases our corporate vision, which is to become a world-class provider of power conversion and control solutions, creating a more sustainable future for our world," Wang emphasized.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527117090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom